WAYNE, Pa.--(BUSINESS WIRE)--Sep. 8, 2014--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
devices for critical care and surgery, announces that its technology
will be the subject of symposiums and scientific presentations at the
upcoming annual meeting of the Association for Vascular Access (AVA).
Teleflex will also host AVA’s first-ever vascular access cadaver lab at
the conference.
AVA 2014 will be held September 7-10 at the Gaylord National Resort and
Convention Center, in National Harbor, MD.
The cadaver lab and several of the Teleflex symposiums and poster
presentations include products from the ARROW® Brand
portfolio. The portfolio includes vascular access devices such as
antimicrobial and antithrombogenic PICCs and CVCs; the ARROW®
VPS G4™ Vascular Positioning System®; and the new ARROW® EZ-IO®
Needle + Stabilizer Kit. These products assist healthcare facilities in
striving to achieve a goal of zero complications in vascular care by
providing protection against catheter infection, thrombosis, occlusion,
and malposition.
Teleflex will be at Booth 221 in Prince George’s Exhibition Hall E
during the conference. At its booth, the company will focus special
attention on its Chlorag+ard® Technology. This
includes the ARROW® JACC with Chlorag+ard®
Technology, the world’s only antimicrobial and antithrombogenic CVC, and
the ARROW® PICC with Chlorag+ard®
Technology, the world’s only antimicrobial and antithrombogenic PICC.
The cadaver lab will provide a unique hands-on opportunity for
participants to practice vascular-access techniques as well as receive
an in-depth review of associated anatomy on cadaveric specimens. It will
be held Monday, September 8 from 7-9 p.m. in Potomac D on the convention
center’s second level.
Other presentations include:
-
Showcase – “You Can’t Afford Not to Understand Affordable Care”
showcase with speaker Leslie Schultz, AN, PhD, CPHQ. 3:30 p.m.,
Monday, September 8, in Potomac 1-2.
-
Dinner Symposium – “Chlorag+ard® Technology:
Reducing a Triad of Associated Complications”, Kamna Giare-Patel, MS,
AN, and Rebekah Limato, BS, ART. Monday, September 8, 7 p.m. in
Potomac C on the second level.
-
Breakfast Symposium – “Preserving Vascular Real Estate: Location is
Important for the Renal Patient.” The speaker is Peter Wayne, MD. 7
a.m. Tuesday, September 9 in Potomac C on the second level.
The following are among 9 poster presentations at AVA evaluating
technology from Teleflex:
-
“Catheter technologies: Is eluting technology or non-eluting
technology more effective in preventing thrombus accumulation?” by
Kamna Giare-Patel, MS, et al. This study evaluated the effectiveness
of three types of peripherally inserted central venous catheters
(PICCs) as compared to uncoated PICCs, in a clinically simulated ovine
model.
-
“Are antibiotic-resistant ‘superbugs’ a real challenge to
antimicrobial central venous catheter performance?” by Nisha Gupta,
PhD, et al. The research compared the in vitro effectiveness of
three antimicrobial CVCs against gram-positive and gram-negative
“superbugs”.
-
“Are PICCs with eluting technology more effective against
antibiotic-resistant bacteria than non-eluting technology?” by Nisha
Gupta, PhD, et al. The authors compared the antimicrobial
effectiveness of three different types of PICCs against six
antibiotic-resistant superbugs.
-
“Can PICC technologies prevent catheter colonization by CLABSI-causing
pathogens?” by Nisha Gupta, PhD, et al. Researchers compared the
antimicrobial effectiveness of three different types of PICCs against
12 common pathogens responsible for causing central line-associated
bloodstream infections (CLABSIs).
The posters will be displayed on Monday, September 8 from 8 a.m. to 5
p.m.; Tuesday, September 9 from 8 a.m. to 5 p.m.; and Wednesday,
September 10 from 7 to 11:30 a.m. Authors will be available to answer
questions about their posters on Monday, Sept. 8 from 8 to 9 a.m. and
Tuesday, September 9 from 8 to 9 a.m.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a
range of procedures in critical care and surgery. Our mission is to
provide solutions that enable healthcare providers to improve outcomes
and enhance patient and provider safety. Headquartered in Wayne, PA,
Teleflex employs approximately 11,500 people worldwide and serves
healthcare providers in more than 150 countries. Additional information
about Teleflex can be obtained from the company's website at teleflex.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, Arrow, Chlorag+ard, EZ-IO,
Vascular Positioning System and VPS G4 are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates.
© 2014 Teleflex Incorporated. All rights reserved. MC-000536
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze, 610-948-2836
Treasurer
and Vice President, Investor Relations